CN1061908A - A kind of manufacture method of curing cancer drug - Google Patents
A kind of manufacture method of curing cancer drug Download PDFInfo
- Publication number
- CN1061908A CN1061908A CN91111835A CN91111835A CN1061908A CN 1061908 A CN1061908 A CN 1061908A CN 91111835 A CN91111835 A CN 91111835A CN 91111835 A CN91111835 A CN 91111835A CN 1061908 A CN1061908 A CN 1061908A
- Authority
- CN
- China
- Prior art keywords
- realgar
- myrrha
- alumen
- weighing
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to a kind of early cervical carcinoma and skin carcinoma manufacture method that contains the arsenic medicine for the treatment of.Be raw material mainly, weigh that processing steps such as high-temperature calcination, cold preservation grinding, composition measurement, mixed-forming are made Chinese medicine tablet, bar, suppository type through pulverizing with arsenicum sablimatum, Alumen, Realgar, Myrrha.The curing cancer drug of producing with this process has easy to use, safety, and good effect, cure rate height, can also keep women's physiological, reproductive function, characteristics such as side effect is extremely light, no sequel are for the patient of vast town and country and cervical cancer district occurred frequently provides easy, medicine efficiently.
Description
The present invention relates to a kind of manufacture method of medical preparation, especially a kind of manufacture method that contains the arsenic curing cancer drug.
Cancer is one of main arch-criminal of world today's threat human life safety, and cervical cancer then is the modal malignant tumor of women, and general at present both at home and abroad employing is performed the operation or X-ray therapy is treated.The report that operative therapys such as employing is freezing, laser, external therapy of Chinese herb are also arranged, but its effect is all unsatisfactory.2539993 of French Patent (FRP)s are called " anticancer wound ointment ", in the external-applied ointment that a kind of purpose is to treat skin carcinoma is disclosed, it mainly contains materials such as arsenic, tapioca starch derivant, hydrogen peroxide, brandy, though be used for that the affected part epidermis is smeared, this anticancer ointment has certain curative effect to skin carcinoma, but because of its medicinal component complexity, especially, more difficult extensive use, and can not be used for treating cervical cancer.
The objective of the invention is to overcome above-mentioned the deficiencies in the prior art and provide a kind of production technology simple, raw material is easy to get contains arsenic curing cancer drug manufacture method, its product is used for the treatment of early cervical carcinoma and the skin carcinoma effect is remarkable, has no side effect, and is easy to use and do not influence physiology and reproductive function.
Purpose of the present invention can reach by following processing step:
A. weighing and burden, the raw material of having pulverized is pressed the weighing of row weight portion proportioning:
Arsenicum sablimatum 30～75, Realgar 2～3,
Alumen 40～100, Myrrha 1～4,
B. high-temperature calcination behind the arsenicum sablimatum of weighing, Alumen powder mix homogeneously, was put into a hermetic container, 550～800 ℃ of temperature lower calcinations 15～20 minutes;
C. cold preservation is ground, and the mixture after calcining is natural cooling at room temperature, places under 3～6 ℃ of temperature cold preservation 12～24 hours, is ground into powder then and by 100 eye mesh screens;
D. measure content, through the fine powder of screen cloth by weight method measure the weight percentage of arsenic trioxide and al arsenate, its numerical value is respectively 15～20 and 4～8.
E. mixed-forming mixes with Realgar, the Myrrha by the said ratio weighing measuring the qualified calcining mixt of content, is processed into various dosage forms such as tablet or bacillum as required.
The present invention can also adopt following technological operation to obtain better effect.
When weighing and burden, selecting the weight proportion of arsenicum sablimatum and Alumen is 3: 4, and the weight proportion of Realgar and Myrrha is 2: 1.
Embodiment:
A. will carry out Weighing by following prescription through the raw material of pulverizing:
Arsenicum sablimatum 45 grams, Realgar 7.2 grams,
Alumen 60 grams, Myrrha 3.6 grams,
B. put into the bique crucible behind arsenicum sablimatum 45 grams of weighing, the Alumen 60 gram mix homogeneously and sealed, in high-temperature electric resistance furnace, be heated to 600 ℃, and kept 15 minutes with yellow mud.
C. the mixture natural cooling at room temperature after calcining puts into temperature and be 4 ℃ refrigerator and cooled and hid 20 hours, and then it is Powdered to place mortar to be ground into, and by 100 eye mesh screens.
D. to the powdery semi-finished product that the sieve mensuration of weighing:
(1) assay method of arsenic trioxide is undertaken by regulation in the Pharmacopoeia of the People's Republic of China nineteen fifty-three version;
(2) analytical method is measured the percentage by weight of arsenic trioxide and al arsenate in the product routinely, its numerical value be respectively 18 and 6(± 2).
E. content is qualified semi-finished product by Realgar 7.2 grams, the Myrrha 3.6 gram mixed together of above-mentioned prescription weighing, are made dosage forms such as sheet, bar with then according to a conventional method.
The present invention has following features compared with prior art:
1, the simple and raw material of production technology is easy to get, and particularly adopts calcine technology to improve the effective component content in the medicine; Adopt refrigeration technology to strengthen the function and efficacy of medicament effective component.
2, pharmaceutical treatment early cervical carcinoma and the cutaneum carcinoma successful produced with the method, have no side effect and more after do not affect physiology and reproductive function.
3, easy to use with tablet, the bacillum of the method production, and long action time, be difficult for perilesional health tissues.
Product of the present invention can be tested by the relevant cavity medication health examination standard of country. Preclinical toxicity test shows: the drug poisoning reaction that the inventive method is produced is similar to arsenical, and local topical can cause that obvious coagulation necrosis takes place the body local organization, and the concentration that is absorbed arsenic in the human body is very low. Such as routinely medication, strictly select indication, can not cause toxic reaction. Through the clinical treatment Research statistics to 230 routine early cervical carcinoma patients, cure rate is 100%, follows up a case by regular visits to and has no recidivist's 198 examples more than 5 years, and relative cure rate also was 100% in 5 years. Four routine I a phase cancer patients each full-term pregnancy in 1 to 6 year after curing is in the recent period wherein arranged, spontaneous labor once and mothers and sons all alive, child (child) intelligence is all in normal range (NR). The statistical effect data of the inventive method products obtained therefrom treatment early cervical carcinoma see the following form:
| Therapy | Phase is other | Treat routine number | Cure in the recent period | Follow up a case by regular visits to five annual bearings | Remarks | |||||
| Strong depositing | Recurrence | |||||||||
| The example number | ％ | The example number | The example number | ％ | The example number | ％ | ||||
| Carcinoma in situ | 137 | 137 | 100.0 | 117 | 109 | 100.0 | 0 | 0 | Cure among the patient in the recent period, the time of following up a case by regular visits to reaches 5-10 person's 198 examples and is showed no recurrence | |
| Ia | 93 | 93 | 100.0 | 81 | 71 | 100.0 | 0 | 0 | ||
Claims (3)
1, a kind of manufacture method of curing cancer drug is a raw material with arsenicum sablimatum, Alumen, Realgar, Myrrha mainly, makes by following processing step:
A. weighing and burden, will press row weight portion proportioning through the raw material of pulverizing and take by weighing:
Arsenicum sablimatum 30～75, Realgar 2～8,
Alumen 40～100, Myrrha 1～4,
B. high-temperature calcination is put into a hermetic container with arsenicum sablimatum, the Alumen powder of weighing, calcines under 550～800 ℃ of temperature, and continues 15～20 minutes;
C. cold preservation is ground, and the mixture after the calcining placed under 3～6 ℃ of temperature cold preservation 12～24 hours after natural cooling, grind to form fine powder then, crossed 100 mesh sieves;
D. measure content, the mixture after cold preservation is ground method by weight contains arsenic mensuration, and wherein the percentage by weight of arsenic trioxide is 15～20, and the percentage by weight of al arsenate is 4～8;
E. mixed-forming mixes qualified after measured calcining mixt with Realgar, the Myrrha of weighing, is processed into tablet, bacillum or other dosage form as required.
2, according to the manufacture method of the described curing cancer drug of claim 1, it is characterized in that above-mentioned raw materials is by arsenicum sablimatum: Alumen is 3: 4, Realgar: Myrrha is 1: 2 optimum weight ratio preparation.
3,, it is characterized in that pressing column weight amount proportioning weighing and burden according to the manufacture method of claim 1 or 2 described curing cancer drugs:
White batch 45, Realgar 7.2,
Alumen 60, Myrrha 3.6,
Optimum calcinating temperature and time are respectively 600 ℃, and 15 minutes, the optimum weight percentage composition arsenic trioxide during assay was 18, and al arsenate is 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN91111835A CN1061908A (en) | 1991-12-21 | 1991-12-21 | A kind of manufacture method of curing cancer drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN91111835A CN1061908A (en) | 1991-12-21 | 1991-12-21 | A kind of manufacture method of curing cancer drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1061908A true CN1061908A (en) | 1992-06-17 |
Family
ID=4910895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN91111835A Pending CN1061908A (en) | 1991-12-21 | 1991-12-21 | A kind of manufacture method of curing cancer drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1061908A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999055344A1 (en) * | 1998-04-24 | 1999-11-04 | Daopei Lu | Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies |
| US6723351B2 (en) | 1997-11-10 | 2004-04-20 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US6875451B2 (en) | 1997-10-15 | 2005-04-05 | Polarx Biopharmaceuticals Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| CN105412243A (en) * | 2015-12-15 | 2016-03-23 | 王金国 | External medicine applied to cervical cancer and preparation method of external medicine |
-
1991
- 1991-12-21 CN CN91111835A patent/CN1061908A/en active Pending
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875451B2 (en) | 1997-10-15 | 2005-04-05 | Polarx Biopharmaceuticals Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| US7205001B2 (en) | 1997-10-15 | 2007-04-17 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| US7179493B2 (en) | 1997-10-15 | 2007-02-20 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| US7163703B2 (en) | 1997-10-15 | 2007-01-16 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| US7132116B2 (en) | 1997-10-15 | 2006-11-07 | Polarx Biopharmaceuticals Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| US6770304B2 (en) | 1997-11-10 | 2004-08-03 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US6861076B2 (en) | 1997-11-10 | 2005-03-01 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US6855339B2 (en) * | 1997-11-10 | 2005-02-15 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US6884439B2 (en) * | 1997-11-10 | 2005-04-26 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US6982096B2 (en) * | 1997-11-10 | 2006-01-03 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US6723351B2 (en) | 1997-11-10 | 2004-04-20 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US7879364B2 (en) * | 1997-11-10 | 2011-02-01 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US8273379B2 (en) | 1997-11-10 | 2012-09-25 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| WO1999055344A1 (en) * | 1998-04-24 | 1999-11-04 | Daopei Lu | Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies |
| US7138147B2 (en) | 1998-04-24 | 2006-11-21 | Daopei Lu | Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies |
| US6733792B1 (en) | 1998-04-24 | 2004-05-11 | Daopei Lu | Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies |
| AU748795B2 (en) * | 1998-04-24 | 2002-06-13 | Daopei Lu | Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies |
| CN105412243A (en) * | 2015-12-15 | 2016-03-23 | 王金国 | External medicine applied to cervical cancer and preparation method of external medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101116503A (en) | Health products for reducing blood sugar and method for preparing the same | |
| CN101524464B (en) | Pure traditional Chinese medicine composition for treating female breast diseases and pure traditional Chinese medicine preparation prepared thereby | |
| CN103608024A (en) | Pharmaceutical composition for controlling blood sugar, blood lipid and body weight | |
| CN1061908A (en) | A kind of manufacture method of curing cancer drug | |
| CN1244120A (en) | New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 G/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof | |
| CN101041015B (en) | Medicine for treating hyperplasia of mammary glands | |
| CN1803152A (en) | Pest-clearing toxicide | |
| CN1271537A (en) | Health-care American ginseng-pollen food and preparing process thereof | |
| CN108323762B (en) | Selenium-rich composition and preparation, preparation method and application thereof | |
| CN105521246A (en) | Medicinal preparation for treating lung cancer and applications of medicinal preparation | |
| CN100352449C (en) | Medicament composition for treating tinea pedis and tinea corporis | |
| CN111000958A (en) | Chinese patent medicine for ovary nursing and preparation method thereof | |
| CN111358834A (en) | Octacosanol composition for improving microcirculation and reducing blood fat and application thereof | |
| CN1088445A (en) | The burn and scald spirit | |
| CN111632113A (en) | Pressed candy with function of repairing kidney function of female | |
| CN109106743A (en) | A kind of blood-activating and pain-stopping capsules and preparation method thereof | |
| CN1520851A (en) | Ulcerative stomatitis powder | |
| CN104547773B (en) | A kind of pharmaceutical composition for treating dysfunctional uterine bleeding | |
| CN115887599B (en) | Pharmaceutical composition for treating herpes zoster and preparation method and application thereof | |
| CN101584828A (en) | Preparation for Chinese medicinal composition for clearing lung-heat | |
| CN1073433C (en) | Medicine for psoriasis and preparing method thereof | |
| CN101317854A (en) | Soft capsule of heart blood of deer | |
| CN101342285A (en) | Chinese medicinal composition for treating exterior trauma and preparation method thereof | |
| CN105853603A (en) | Yao medicine composition for treating insomnia and preparation method thereof | |
| CN1186679A (en) | Medicine for curing pulmonary tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication |